DOACs Linked to Lower Stroke and Bleeding in Elderly AF

This decade-long nationwide cohort provides real-world outcome data on DOAC, warfarin, and no-anticoagulation strategies in AF patients aged 75 and older, a population underrepresented in pivotal trials.

DOACapixabanrivaroxabandabigatranwarfarinatrial fibrillationelderlystroke preventionintracranial hemorrhagegastrointestinal bleedinganticoagulationretrospective cohortreal-world evidence Cardiology / Anticoagulation

Background Information

DOACs safely reduce stroke risk in elderly AF patients.

Direct oral anticoagulants (DOACs) are increasingly used in elderly patients with atrial fibrillation (AF), offering a safer alternative to warfarin. DOACs were associated with reduced stroke and gastrointestinal bleeding (GIB) risks compared to non-users: stroke risk reduced by 29% and GIB by 19%. The study confirms DOACs as a safer option than warfarin in elderly AF patients, reducing stroke and gastrointestinal bleeding risks without increasing intracranial hemorrhage (ICH) risk. DOACs are a safer, effective option for managing atrial fibrillation in elderly patients.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Alnsasra H, Tsaban G, Ostrovsky D, Livne N, Filderman B, Henkin Y, Iakobishvili Z, Arnson Y, Eisen A, Weisband Y, Schliamser J, Haim M

Citation: Alnsasra H, Tsaban G, Ostrovsky D, et al. Direct oral anticoagulants in elderly patients with atrial fibrillation: a decade-long nationwide retrospective cohort study. BMJ open. 2026;16(8):e121683. doi:10.1136/bmjopen-2026-121683

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →